The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update
Pseudomonas aeruginosa is a Gram-negative bacterial pathogen that is a common cause of nosocomial infections, particularly pneumonia, infection in immunocompromised hosts, and in those with structural lung disease such as cystic fibrosis. Epidemiological studies have identified increasing trends of...
Gespeichert in:
| Veröffentlicht in: | Drugs (New York, N.Y.) N.Y.), 2021-12, Vol.81 (18), p.2117-2131 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2131 |
|---|---|
| container_issue | 18 |
| container_start_page | 2117 |
| container_title | Drugs (New York, N.Y.) |
| container_volume | 81 |
| creator | Reynolds, Dan Kollef, Marin |
| description | Pseudomonas aeruginosa
is a Gram-negative bacterial pathogen that is a common cause of nosocomial infections, particularly pneumonia, infection in immunocompromised hosts, and in those with structural lung disease such as cystic fibrosis. Epidemiological studies have identified increasing trends of antimicrobial resistance, including multi-drug resistant (MDR) isolates in recent years.
P. aeruginosa
has several virulence mechanisms that increase its ability to cause severe infections, such as secreted toxins, quorum sensing and biofilm formation. Management of
P. aeruginosa
infections focuses on prevention when possible, obtaining cultures, and prompt initiation of antimicrobial therapy, occasionally with combination therapy depending on the clinical scenario to ensure activity against
P. aeruginosa
. Newer anti-pseudomonal antibiotics are available and are increasingly being used in the management of MDR
P. aeruginosa
. |
| doi_str_mv | 10.1007/s40265-021-01635-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8572145</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2595108963</sourcerecordid><originalsourceid>FETCH-LOGICAL-c523t-f223f6b1f16df4cda45eb5fd784d5879539f3d9d5ead994148fa5bd3d02d8d583</originalsourceid><addsrcrecordid>eNp9kU9P3DAQxa2qqGyhX4BDFamXXgL-n5gDEkK0ICHBYTlb3nicNUrsrZ1U4tvXsECBA6eR5_3meUYPoQOCDwnGzVHmmEpRY0pqTCQTtfyEFoQ0qiZK4M9ogTGhtZSy2UVfc757eCqhvqBdxhvOGBELpJdrqM433sLo4xD7-8oEW92YaR17CJB9fmwsE5hphDBV0VU3GWYbxxhMESHNvQ8xm-oyOOgmH0M-rk5DdbuxZoJ9tOPMkOHbU91Dt7_Ol2cX9dX178uz06u6E5RNtaOUObkijkjreGcNF7ASzjYtt6JtlGDKMausAGOV4oS3zoiVZRZT2xaC7aGTre9mXo1gu7JqMoPeJD-adK-j8fqtEvxa9_GvbkVDCRfF4OeTQYp_ZsiTHn3uYBhMgDhnTYUSBLdKsoL-eIfexTmFcp6mErcCN8W0UHRLdSnmnMC9LEOwfshPb_PTJT_9mJ-WZej76zNeRp4DKwDbArlIoYf0_-8PbP8BMkCnlw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2608507857</pqid></control><display><type>article</type><title>The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Reynolds, Dan ; Kollef, Marin</creator><creatorcontrib>Reynolds, Dan ; Kollef, Marin</creatorcontrib><description>Pseudomonas aeruginosa
is a Gram-negative bacterial pathogen that is a common cause of nosocomial infections, particularly pneumonia, infection in immunocompromised hosts, and in those with structural lung disease such as cystic fibrosis. Epidemiological studies have identified increasing trends of antimicrobial resistance, including multi-drug resistant (MDR) isolates in recent years.
P. aeruginosa
has several virulence mechanisms that increase its ability to cause severe infections, such as secreted toxins, quorum sensing and biofilm formation. Management of
P. aeruginosa
infections focuses on prevention when possible, obtaining cultures, and prompt initiation of antimicrobial therapy, occasionally with combination therapy depending on the clinical scenario to ensure activity against
P. aeruginosa
. Newer anti-pseudomonal antibiotics are available and are increasingly being used in the management of MDR
P. aeruginosa
.</description><identifier>ISSN: 0012-6667</identifier><identifier>EISSN: 1179-1950</identifier><identifier>DOI: 10.1007/s40265-021-01635-6</identifier><identifier>PMID: 34743315</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Anti-Bacterial Agents - therapeutic use ; Antibiotics ; Antimicrobial resistance ; Biofilms ; Biofilms - drug effects ; Bronchiectasis - epidemiology ; Cross Infection - drug therapy ; Cross Infection - epidemiology ; Cystic fibrosis ; Cystic Fibrosis - epidemiology ; Drug resistance ; Drug Resistance, Multiple, Bacterial - physiology ; Epidemiology ; Gram-negative bacteria ; Humans ; Immunocompromised Host ; Immunocompromised hosts ; Infection Control - organization & administration ; Internal Medicine ; Lung diseases ; Medicine ; Medicine & Public Health ; Microbial Sensitivity Tests ; Mortality ; Multidrug resistance ; Nosocomial infection ; Nosocomial infections ; Pathogenesis ; Pharmacology/Toxicology ; Pharmacotherapy ; Pseudomonas aeruginosa ; Pseudomonas Infections - drug therapy ; Pseudomonas Infections - epidemiology ; Pseudomonas Infections - prevention & control ; Quorum sensing ; Quorum Sensing - drug effects ; Review ; Review Article ; Toxins ; Urinary tract infections ; Virulence</subject><ispartof>Drugs (New York, N.Y.), 2021-12, Vol.81 (18), p.2117-2131</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</rights><rights>Copyright Springer Nature B.V. Dec 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c523t-f223f6b1f16df4cda45eb5fd784d5879539f3d9d5ead994148fa5bd3d02d8d583</citedby><cites>FETCH-LOGICAL-c523t-f223f6b1f16df4cda45eb5fd784d5879539f3d9d5ead994148fa5bd3d02d8d583</cites><orcidid>0000-0003-0671-0751</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40265-021-01635-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40265-021-01635-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34743315$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reynolds, Dan</creatorcontrib><creatorcontrib>Kollef, Marin</creatorcontrib><title>The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update</title><title>Drugs (New York, N.Y.)</title><addtitle>Drugs</addtitle><addtitle>Drugs</addtitle><description>Pseudomonas aeruginosa
is a Gram-negative bacterial pathogen that is a common cause of nosocomial infections, particularly pneumonia, infection in immunocompromised hosts, and in those with structural lung disease such as cystic fibrosis. Epidemiological studies have identified increasing trends of antimicrobial resistance, including multi-drug resistant (MDR) isolates in recent years.
P. aeruginosa
has several virulence mechanisms that increase its ability to cause severe infections, such as secreted toxins, quorum sensing and biofilm formation. Management of
P. aeruginosa
infections focuses on prevention when possible, obtaining cultures, and prompt initiation of antimicrobial therapy, occasionally with combination therapy depending on the clinical scenario to ensure activity against
P. aeruginosa
. Newer anti-pseudomonal antibiotics are available and are increasingly being used in the management of MDR
P. aeruginosa
.</description><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Antimicrobial resistance</subject><subject>Biofilms</subject><subject>Biofilms - drug effects</subject><subject>Bronchiectasis - epidemiology</subject><subject>Cross Infection - drug therapy</subject><subject>Cross Infection - epidemiology</subject><subject>Cystic fibrosis</subject><subject>Cystic Fibrosis - epidemiology</subject><subject>Drug resistance</subject><subject>Drug Resistance, Multiple, Bacterial - physiology</subject><subject>Epidemiology</subject><subject>Gram-negative bacteria</subject><subject>Humans</subject><subject>Immunocompromised Host</subject><subject>Immunocompromised hosts</subject><subject>Infection Control - organization & administration</subject><subject>Internal Medicine</subject><subject>Lung diseases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Microbial Sensitivity Tests</subject><subject>Mortality</subject><subject>Multidrug resistance</subject><subject>Nosocomial infection</subject><subject>Nosocomial infections</subject><subject>Pathogenesis</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Pseudomonas aeruginosa</subject><subject>Pseudomonas Infections - drug therapy</subject><subject>Pseudomonas Infections - epidemiology</subject><subject>Pseudomonas Infections - prevention & control</subject><subject>Quorum sensing</subject><subject>Quorum Sensing - drug effects</subject><subject>Review</subject><subject>Review Article</subject><subject>Toxins</subject><subject>Urinary tract infections</subject><subject>Virulence</subject><issn>0012-6667</issn><issn>1179-1950</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kU9P3DAQxa2qqGyhX4BDFamXXgL-n5gDEkK0ICHBYTlb3nicNUrsrZ1U4tvXsECBA6eR5_3meUYPoQOCDwnGzVHmmEpRY0pqTCQTtfyEFoQ0qiZK4M9ogTGhtZSy2UVfc757eCqhvqBdxhvOGBELpJdrqM433sLo4xD7-8oEW92YaR17CJB9fmwsE5hphDBV0VU3GWYbxxhMESHNvQ8xm-oyOOgmH0M-rk5DdbuxZoJ9tOPMkOHbU91Dt7_Ol2cX9dX178uz06u6E5RNtaOUObkijkjreGcNF7ASzjYtt6JtlGDKMausAGOV4oS3zoiVZRZT2xaC7aGTre9mXo1gu7JqMoPeJD-adK-j8fqtEvxa9_GvbkVDCRfF4OeTQYp_ZsiTHn3uYBhMgDhnTYUSBLdKsoL-eIfexTmFcp6mErcCN8W0UHRLdSnmnMC9LEOwfshPb_PTJT_9mJ-WZej76zNeRp4DKwDbArlIoYf0_-8PbP8BMkCnlw</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Reynolds, Dan</creator><creator>Kollef, Marin</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7QO</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0671-0751</orcidid></search><sort><creationdate>20211201</creationdate><title>The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update</title><author>Reynolds, Dan ; Kollef, Marin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c523t-f223f6b1f16df4cda45eb5fd784d5879539f3d9d5ead994148fa5bd3d02d8d583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Antimicrobial resistance</topic><topic>Biofilms</topic><topic>Biofilms - drug effects</topic><topic>Bronchiectasis - epidemiology</topic><topic>Cross Infection - drug therapy</topic><topic>Cross Infection - epidemiology</topic><topic>Cystic fibrosis</topic><topic>Cystic Fibrosis - epidemiology</topic><topic>Drug resistance</topic><topic>Drug Resistance, Multiple, Bacterial - physiology</topic><topic>Epidemiology</topic><topic>Gram-negative bacteria</topic><topic>Humans</topic><topic>Immunocompromised Host</topic><topic>Immunocompromised hosts</topic><topic>Infection Control - organization & administration</topic><topic>Internal Medicine</topic><topic>Lung diseases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Microbial Sensitivity Tests</topic><topic>Mortality</topic><topic>Multidrug resistance</topic><topic>Nosocomial infection</topic><topic>Nosocomial infections</topic><topic>Pathogenesis</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Pseudomonas aeruginosa</topic><topic>Pseudomonas Infections - drug therapy</topic><topic>Pseudomonas Infections - epidemiology</topic><topic>Pseudomonas Infections - prevention & control</topic><topic>Quorum sensing</topic><topic>Quorum Sensing - drug effects</topic><topic>Review</topic><topic>Review Article</topic><topic>Toxins</topic><topic>Urinary tract infections</topic><topic>Virulence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reynolds, Dan</creatorcontrib><creatorcontrib>Kollef, Marin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Drugs (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reynolds, Dan</au><au>Kollef, Marin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update</atitle><jtitle>Drugs (New York, N.Y.)</jtitle><stitle>Drugs</stitle><addtitle>Drugs</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>81</volume><issue>18</issue><spage>2117</spage><epage>2131</epage><pages>2117-2131</pages><issn>0012-6667</issn><eissn>1179-1950</eissn><abstract>Pseudomonas aeruginosa
is a Gram-negative bacterial pathogen that is a common cause of nosocomial infections, particularly pneumonia, infection in immunocompromised hosts, and in those with structural lung disease such as cystic fibrosis. Epidemiological studies have identified increasing trends of antimicrobial resistance, including multi-drug resistant (MDR) isolates in recent years.
P. aeruginosa
has several virulence mechanisms that increase its ability to cause severe infections, such as secreted toxins, quorum sensing and biofilm formation. Management of
P. aeruginosa
infections focuses on prevention when possible, obtaining cultures, and prompt initiation of antimicrobial therapy, occasionally with combination therapy depending on the clinical scenario to ensure activity against
P. aeruginosa
. Newer anti-pseudomonal antibiotics are available and are increasingly being used in the management of MDR
P. aeruginosa
.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>34743315</pmid><doi>10.1007/s40265-021-01635-6</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0003-0671-0751</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-6667 |
| ispartof | Drugs (New York, N.Y.), 2021-12, Vol.81 (18), p.2117-2131 |
| issn | 0012-6667 1179-1950 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8572145 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Anti-Bacterial Agents - therapeutic use Antibiotics Antimicrobial resistance Biofilms Biofilms - drug effects Bronchiectasis - epidemiology Cross Infection - drug therapy Cross Infection - epidemiology Cystic fibrosis Cystic Fibrosis - epidemiology Drug resistance Drug Resistance, Multiple, Bacterial - physiology Epidemiology Gram-negative bacteria Humans Immunocompromised Host Immunocompromised hosts Infection Control - organization & administration Internal Medicine Lung diseases Medicine Medicine & Public Health Microbial Sensitivity Tests Mortality Multidrug resistance Nosocomial infection Nosocomial infections Pathogenesis Pharmacology/Toxicology Pharmacotherapy Pseudomonas aeruginosa Pseudomonas Infections - drug therapy Pseudomonas Infections - epidemiology Pseudomonas Infections - prevention & control Quorum sensing Quorum Sensing - drug effects Review Review Article Toxins Urinary tract infections Virulence |
| title | The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T00%3A59%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Epidemiology%20and%20Pathogenesis%20and%20Treatment%20of%20Pseudomonas%20aeruginosa%20Infections:%20An%20Update&rft.jtitle=Drugs%20(New%20York,%20N.Y.)&rft.au=Reynolds,%20Dan&rft.date=2021-12-01&rft.volume=81&rft.issue=18&rft.spage=2117&rft.epage=2131&rft.pages=2117-2131&rft.issn=0012-6667&rft.eissn=1179-1950&rft_id=info:doi/10.1007/s40265-021-01635-6&rft_dat=%3Cproquest_pubme%3E2595108963%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2608507857&rft_id=info:pmid/34743315&rfr_iscdi=true |